Pretreatment with tetramethylpyrazine increases the release of PGI2 and decreases TXA2 release in isolated rat heart.
We investigated the release of PGI2 and TXA2 by measuring their stable metabolites of 6-keto-PGF1a and TXB2 in the perfusate in the isolated rat heart after pretreatment with tetramethylpyrazine (TMP). Pretreatment with TMP (12 mg/kg, i.p.) 7 days before preparation produced a significant elevation of 6-keto-PGF1a from 2.30 +/- 0.65 ng/min/g of untreated controls to 3.8 +/- 0.77 ng/mir/g (p < 0.05). Pretreatment with TMP also decreased TXB2 release (p < 0.05 versus control).
Feng
J
J
Liu
R
R
Wu
G
G
Tang
S
S
D015121:6-Ketoprostaglandin F1 alpha / Q000378:metabolism; D000818:Animals; D011464:Epoprostenol / Q000378:metabolism*; D006321:Heart / Q000187:drug effects*; D066298:In Vitro Techniques; D008297:Male; D009206:Myocardium / Q000378:metabolism*; D011719:Pyrazines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012016:Reference Values; D013928:Thromboxane A2 / Q000378:metabolism*; D014665:Vasodilator Agents / Q000494:pharmacology*
D011719:Pyrazines; D014665:Vasodilator Agents; D013928:Thromboxane A2; D015121:6-Ketoprostaglandin F1 alpha; D011464:Epoprostenol; C017953:tetramethylpyrazine